Animal cells internalize specific extracellular macromolecules (ligands) by using specialized
cell surface receptors that operate through a complex and highly regulated process known …

Introduction 3. Asialoglycoprotein receptor 3.1. Biology of asialoglycoprotein receptor (ASGP-
R) 3.2. Carbohydrate recognition domain (CRD) 3.3 Internalization of the ligands by ASGP …

Every day, megakaryocytes produce billions of platelets that circulate for several days and
eventually are cleared by the liver. The exact removal mechanism, however, remains …

Targeted delivery of therapeutic agents to hepatocytes is a particularly attractive strategy for
the treatment of hepatocellular carcinoma and other liver diseases. The asialoglycoprotein …

Abstract The Ashwell–Morell receptor (AMR) of hepatocytes, originally termed the hepatic
asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and …

Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the
asialoglycoprotein receptor (ASGR) has improved the potency of ASO drugs∼ 30-fold in the …

Aim One of the most promising strategies for the treatment of liver diseases is targeted drug
delivery via the asialoglycoprotein receptor (ASGPR). The success of this approach heavily …

Oligonucleotide therapeutics have emerged as a third distinct platform for drug discovery
within the pharmaceutical industry. Five oligonucleotide-based drugs have been approved …

Antisense oligonucleotides (ASOs) conjugated to trivalent GalNAc ligands show 10-fold
enhanced potency for suppressing gene targets expressed in hepatocytes. Trivalent GalNAc …

To improve liposome‐directed therapy of liver disease and gene delivery, it would be
beneficial to selectively target hepatocytes. For this purpose, conventional liposomes (CL) …